49.30 +0.17 (0.35%)
After hours: 7:56PM EST
|Bid||0.00 x 900|
|Ask||0.00 x 1800|
|Day's Range||49.10 - 50.26|
|52 Week Range||44.30 - 70.05|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||56.28|
|Forward Dividend & Yield||1.64 (3.42%)|
|1y Target Est||N/A|
First I-O/I-O combination regimen to receive European approval for previously untreated patients with advanced renal cell carcinoma
NEW ORLEANS , Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Bristol-Myers Squibb announced a deal Thursday, buying Celgene Corp. for $74 billion. Investors in other growing cancer treatment companies should pay attention, ...
Bristol-Myers Squibb Company today announced that Giovanni Caforio, M.D., chairman and chief executive officer, will join Mark Alles, chairman and chief executive officer of Celgene, for a fireside chat at the 37th Annual J.P.
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical.
NEW YORK, Jan. 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Celgene Corporation (“Celgene” or.
NEW YORK, NY / ACCESSWIRE / January 4, 2019 / U.S. markets plunged on Thursday, with the Dow Jones falling more than 600 points, as fears of a possibility of a global economic slowdown intensified after Apple lowered revenue forecasts. The Dow Jones Industrial Average dropped 2.83 percent to close at 22,686.22, dragged mostly lower by losses in Apple’s stock, while the S&P 500 Index decreased 2.48 percent to close at 2,447.89. The Nasdaq Composite Index slumped 3.04 percent to close at 6,463.50.
SAN DIEGO , Jan. 3, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Celgene Corporation (NASDAQ: CELG) ("Celgene") ...
Bristol-Myers Squibb (BMY) today announced EPS guidance for full-year 2019. Bristol-Myers Squibb is providing its 2019 GAAP EPS guidance range at $3.75 to $3.85 and non-GAAP EPS guidance range at $4.10 to $4.20. Bristol-Myers Squibb will provide full line-item guidance for when the company reports its results for the fourth quarter 2018 on January 24, 2019.
Bristol-Myers Squibb Company (BMY) and Celgene Corporation (CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene.
#FDA approves $BMY therapy for certain pediatric patients with a type of acute lymphoblastic leukemia.
NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
Bristol-Myers Squibb Company (BMY) today announced that Taisho Pharmaceutical Holdings Co., Ltd. (Taisho) has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion. UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries.
Bristol-Myers Squibb Company (BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors. “Our newly opened R&D site in Kendall Square is focused on better understanding, and ultimately overcoming, the challenge of I-O resistance. Through the study, researchers will explore the role of tissue and circulating biomarkers on treatment sensitivity and resistance.
The new collaboration will explore modulating RNA splicing to develop potential first-in-class therapies that would direct the immune system to target cancer cells and help more patients experience the benefits of immunotherapy.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the expanded approval of Sprycel , in combination with chemotherapy, to include the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia .
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. ...
Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.
The Board of Directors of Bristol-Myers Squibb Company (BMY) today declared an increase of 2.5% percent in the company’s quarterly dividend, beginning in the first quarter of 2019. The dividend increase will result in a quarterly dividend of 41 cents ($0.41) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on February 1, 2019, to stockholders of record at the close of business on January 4, 2019.
Bristol-Myers Squibb Company will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019. During a conference call at 10:30 a.m. ET on January 24, company executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Company (BMY) today announced it will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan (the “Plan”). The obligations will be distributed through a combination of lump sums to Plan participants who elect such payments, and the purchase of a group annuity contract from Athene Annuity and Life Company (“Athene”), a wholly-owned insurance subsidiary of Athene Holding, Ltd (ATH), for all remaining liabilities. This transaction continues the Company’s pension de-risking strategy and actions, which began with the freezing of the Company’s U.S. Plan in 2009.
Nineteen presentations and publications featuring data from three Bristol-Myers Squibb medicines, alone and in combination, across four hematologic malignancies
Bristol-Myers Squibb Company will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York. Tom Lynch, chief scientific officer, will answer questions about the company at 2:10 p.m.